Diss. (sammanfattning) Uppsala : Univ., 2004. / Härtill 5 uppsatser.

Floral color change is a widespread phenomenon in angiosperms, but poorly understood from the genetic and chemical point of view. This thesis aimed to investigate this phenomenon in Tibouchina pulcha, a native species whose flowers change from white to dark pink. To reach this goal, flavonoid biosynthetic gene expression and compounds were profiled. By using hyphenated techiniques (UPLC-HRMS and NMR), thirty phenolic compounds were quantified and identified, being sixteen described for the first time in T. pulchra. Moreover, an inedite compound was also identified. Five key genes of the flavonoid biosynthetic pathway were partially cloned, sequenced, and the mRNA levels were analyzed (RT-qPCR) along flower development. Collectively, the obtained results demonstrated that the flower color change in T. pulchra is regulated at transcriptional level. Additionally, a metal quantification suggests that Fe3+ ion might influence the saturation of the color at dark pink stage / A mudança de cor em flores é um fenômeno generalizado entre as angiospermas, mas pouco compreendido do ponto de vista genético e químico. Este estudo teve como objetivo investigar esse fenômeno em Tibouchina pulcha , uma espécie nativa brasileira, cujas flores mudam do branco para rosa escuro. Para alcançar o objetivo, os perfis dos compostos e de expressão de genes da via de biossíntese de flavonoides foram estudados. Utilizando técnicas hifenadas (UPLC-HRMS and NMR), trinta compostos foram quantificados e identificados, sendo: dezesseis descritos pela promeira vez em T. pulchra. Além idsso, um composto inédito foi identificado. Cinco genes que codificam para enzimas chaves da via foram parcialmente clonados, sequenciados, e os níveis de mRNA foram analisados (RT-qPCR) durante o desenvolvimento das flores. Coletivamente, os dados obtidos demonstram que a mudança de cor em flores de T. pulchra é regulada transcricionalmente. Além disso, quantificações de metais sugerem que o ion Fe3+ esteja relacionado a saturação da cor no estágio rosa escuro

The BEACH family proteins are conserved in all eukaryotes and are important for membrane trafficking. Defects in specific BEACH proteins have been linked to severe human disorders. For example, loss of human LYST protein causes the Chediak-Higashi Syndrome (CHS), a lethal disorder that affects lysosomal function. I postulate that different classes of BEACH proteins contribute distinct cellular functions in specific organelles. Based on this functional specificity, I hypothesize that each class of BEACH proteins must localize to their respective organelle where they are known to function. Unfortunately, the localization of most mammalian BEACH proteins is not known and no localization signal has been determined for any BEACH protein. Previous work showed that the Dictyostelium LvsA protein localizes and functions on the contractile vacuole while LvsB localizes and functions on the lysosome. Thus, Dictyostelium is a good model system to understand how BEACH proteins localize to specific organelles. Using a knock-in approach and parasexual techniques, I generated a collection of LvsA truncation mutants tagged with GFP and expressed them in different cell lines. Hence I can test the ability of each mutant protein to localize on contractile vacuoles by fluorescence microscopy. I show here that LvsA requires two regions to localize on the contractile vacuole: the N-terminal 140-457 amino acids and the BEACH. In addition, the expression of the N-terminal 651 amino acids of LvsA causes a dominant negative effect suggesting a possible functional protein-protein interaction within this region. Furthermore, sequence alignment analysis shows that this N-terminal region is only conserved within each class of BEACH family proteins. This finding supports our hypothesis and suggests that diversity within the N-terminal region may be due to the specialized targeting sequences of each class of BEACH proteins. Taken together, these results suggest that the conserved BEACH domain may serve as a general localization sequence while the N-terminal segment is responsible for targeting these proteins to their distinct organelles. This study will facilitate the identification of localization signals in other BEACH proteins which is important to dissect the molecular mechanism of their respective functions. / text

Syftet med denna studie är att undersöka huruvida ett lands finansiella system har en effekt på företagssektorns finansiella risker Studien bygger på en kvantitativ ansats där vi samlat in data genom årsredovisningar och annan offentlig marknadsdata. I det empiriska material som togs fram presenterades en förutsägelse för konkurs på över 100 företag under totalt 467 observationer de senaste fem åren (2011-2015). Resultatet visade att företagen i de marknadsorienterade länderna påvisade en högre risk för att hamna i konkurs än de bankorienterade. / The purpose of this study is to investigate whether a country's financial system has an impact on the corporate sector's financial risks. The study is based on a quantitative approach in which we collected data from annual reports and other public market data. In the empirical material that was produced we presented a prediction of bankruptcy over 100 companies with a total of 467 observations over the past five years (2011-2015). The results showed that companies in the marketoriented countries have a higher risk of ending up in bankruptcy than in the bank-oriented countries.

Abstract Background: Golf is a sport with a growing focus on the physical aspect of the game and its relationship to performance. Studies have determined a correlation between club head speed and performance in golf. Rotational power has proven to be an important factor for the club head speed. By examining the relationship between club head speed and rotational power, researchers has found that rotation power on the golfers dominant side have a moderate to high correlation with club head speed. Previous research has mostly investigated the peak rotational power on the dominant side. Furthermore, additional research is needed to examine the bilateral strength and its relationship to club head speed. Aim: The aim of this study was to examine the correlation between peak trunk rotational power and club head speed in elite golfers, and also to study the impact of bilateral rotational strength on club head speed. Methods: The study included 27 elite golf players (21 males, 6 females) age 19±2 years. The subjects attended two sessions where the first session included a club head speed test and the second session a rotation power test in the Quantum machine. The rotational peak power ratio (dominant/non-dominant side) were ranged from 1-27 (the closer to 1, the higher order) to study a linier relationship with club head speed. Spearman’s nonparametric rank correlations coefficient (rs) was used since the data was not normally distributed. Results: There was a moderate correlation between peak trunk rotational power on the dominant side and club head speed ( rs=0.58, p=0.01). The correlation between the peak trunk rotational powers on the dominant and non- dominant side was high, rs=0.82 (p=0.01). There were no significant correlation found between the ranged rotational peak power ratio and club head speed (rs=0.30, p=0.1). Conclusion: The current study found a slightly lower correlation between peak trunk rotational power and club head speed than found in earlier studies. The golfers in this study had symmetric strength in the trunk, other studies have shown that the rotational strength in golfer´s dominant side were higher than of the non- dominant side. The result of this study indicates that balance between the sides not necessarily has a relationship with how high the golfer’s club head speed is. Future research is needed to analyze the quadratic correlation between ratio and club head speed on a more advanced level. The results of this study can, if validated, be used for further researching and understanding of club head speed and golf performance.

<p>Antitumour properties of the cyanoguanidine CHS 828 and analogues were discovered in 1997. CHS 828 is presently in clinical phase I/II trials. This thesis encompasses in vitro studies of the kinetics and mode of cell death induced in the human cell line U-937 GTB, by CHS 828 and the standard antitumour drug etoposide.</p><p>Etoposide induces apoptosis in U-937 GTB within 4 h. The cells exhibited apoptotic morphology, including condensed and fragmented nuclei and formation of apoptotic bodies, activation of caspase 3 and 8, and DNA fragmentation, visualised by TdT-mediated dUTP nick end-labelling (TUNEL).</p><p>CHS 828 induced few and weak signs of apoptosis. Metabolic activity was the only parameter affected during the first 24 h of exposure. After ~30 h, proliferation (DNA synthesis) and protein synthesis ceased, and viability started to decrease towards 10% at 72 h. Morphology and ultrastructure of dying/dead cells showed predominant necrosis. The decrease in viability was postponed by protein synthesis inhibition or maintenance of ATP levels by 3-aminobenzamide. In addition, 3-aminobenzamide switched morphology towards apoptosis. </p><p>Continuous co-exposure to CHS 828 and etoposide resulted in impressive cell kill synergy in U-937 GTB cells at effect levels of 30-70%. Pre-exposure to CHS 828 for 18 h or more, on the other hand, resulted in diminished cell kill and inability to activate the apoptotic machinery upon etoposide stimulation, evaluated by morphology and caspase activity.</p><p>In summary, CHS 828 induced cell death is predominantly non-apoptotic, does not involve caspases and can be postponed by maintained protein synthesis and ATP levels.</p>

<p>Neuroblastoma is one of the most common solid cancers of early childhood. In Sweden, approximately 10-15 cases occur annually. The overall five-year neuroblastoma survival in Europe is approximately 45%. Since cancer treatment involves drugs with risks of side effects in the growing child, there is a need for more effective and less toxic drugs. One new approach in cancer treatment is inhibition of tumor angiogenesis, i.e., of new blood vessel growth into the tumor. An angiogenesis inhibitor may be combined with cytostatic drugs to enhance the efficacy. The aim of this study was to investigate how drugs could be used to inhibit angiogenesis and tumor growth in a xenograft model of human neuroblastoma in nude mice. </p><p>The tumors express the angiogenesis stimulator vascular endothelial growth factor (VEGF) on both protein and mRNA levels. The angiogenesis inhibitors SU5416 (an inhibitor of VEGF signalling) and TNP-470 (an inhibitor of endothelial cell proliferation) inhibited angiogenesis in our model. TNP-470, however, inhibited angiogenesis without significant reduction of the tumor growth, in contrast to SU5416. </p><p>We also discovered that the cytostatic drug CHS 828 could cause regression of neuroblastoma tumors in the model when given orally at a low daily dose, alone or in combination with the angiogenesis inhibitor SU5416 or TNP-470. </p><p>Furthermore, a new use of the cardiac glycoside digoxin was found. Digoxin inhibited FGF-2 -stimulated bovine capillary endothelial cell growth in vitro, and inhibited angiogenesis in vivo in the chick chorioallantoic membrane assay (CAM). It also inhibited neuroblastoma growth by approximately 50% in our neuroblastoma model. </p><p>In conclusion, CHS 828 and digoxin represent two classes of drugs with potent antitumor effects that may be valuable in treatment of neuroblastoma, either alone or in combination with angiogenesis inhibitors.</p>

<p>The antitumoural cyanoguanidine CHS 828 has shown promising activity in a number of preclinical and clinical studies. However, the mechanisms underlying the cell death induced by CHS 828 has not been clarified. This thesis describes in vitro studies of the cellular pharmacology of CHS 828.</p><p>CHS 828 induced cell death with necrosis like features in the lymphoma cell line U-937 GTB. Addition of 3-aminobenzamide, an inhibitor of ADP-ribosylation, resulted in a decreased sensitivity to CHS 828 and a shift in the mode of cell death towards apoptosis. </p><p>Mouse fibroblasts lacking the enzyme PARP-1 were more sensitive to CHS 828 compared to normal fibroblasts. CHS 828 was able to induce p53 in normal fibroblasts but this effect does not seem to be necessary to induce cell death.</p><p>Characterization of two CHS 828 resistant cell lines indicated that they were selectively resistant to cyanoguanidines. Known mechanisms of anticancer drug resistance did not seem to account for the cyanoguanidine resistance. One possible resistance mediating protein, which was upregulated in the resistant cells, was epidermal fatty acid binding protein.</p><p>A novel high content screening assay was also developed. The assay was shown to be suitable both for screening of potential novel antitumoural substances as well for mechanistic studies. In the assay, CHS 828 induced caspase-3 activity and reduction in mitochondrial membrane potential, both signs of apoptosis, in U-937 GTB cells. However, nuclei in exposed cells did not show nuclear fragmentation, one of the hallmarks of apoptosis.</p><p>CHS 828 was also shown to indirectly inhibit the proteasome activity in U-937 GTB cells. </p><p>In conclusion, the results presented provide new insights into the metabolic and molecular events involved in cell death induced by CHS 828.</p>

<p>The novel cyanoguanidine CHS 828 has shown promising antitumor activity in many in vitro and in vivo studies. </p><p>The long-term 14 days in vitro hollow fiber cultures, where tumor cells from different tumor cell lines were cultured inside semipermeable fibers, were more resistant to CHS 828 and other cytotoxic drugs than the shorter-term 3 days cultures. CHS 828 was generally more effective against haematological than solid tumor cells from both cell lines and patients samples. </p><p>In vivo, the hollow fibers were implanted into immunocompetent rats and the pharmacokinetics, tumor response and/or toxicity (pharmacodynamics) of CHS 828 were successfully assayed. CHS 828 showed higher activity in this model when a more protracted schedule was used. The quantitative relationships between dose, plasma concentration and response (PK/PD model) developed for CHS 828 explained this phenomenon partly by dose-dependent fraction absorbed and partly by a schedule-dependent pharmacodynamic effect.</p><p>Modelling of the in vitro CHS 828 and standard cytotoxic drugs concentration-time effect data in different tumor cell types and characterization of pattern of change of the potency and the slope of the concentration-time effect curves were performed. The results suggest two different mechanisms of action for CHS 828 and that CHS 828 cytotoxicity may depend on the schedule used.</p><p>The NF-kB pathway that regulates the transcription of anti-apoptotic genes proved to be inhibited by CHS 828 in different tumor cell lines and the inhibition was correlated to the cell death induced by this agent. CHS 828 did not seem to induce the NF-kB inhibition by affecting the proteasome activity. </p><p>The in vitro and in vivo hollow fiber methods were also used successfully to evaluate the new paclitaxel formulation, Pacliex. Pacliex had a similar activity to that of the clinically used formulation Taxol®.</p>

<p>CHS 828 is a cyanoguanidine with anti-tumour properties which has shown promising effects in several preclinical models. This thesis describes both preclinical and clinical studies aiming to investigate disease specific activity, clinical tolerability and efficacy of CHS 828.</p><p>In paper I we investigated CHS 828 activity in a cell line panel with human myeloma cells, three of these cell-lines were also tested in vivo using a hollow fibre rat-model. In paper II we investigated CHS 828 activity in primary human tumour samples from patients. CHS 828 showed an effect on all tumour cell types tested both the primary human tumour samples and the myeloma cell lines. Notably, CHS 828 showed a high relative in vitro activity against tumour cells from chronic lymphocytic leukaemia and high-grade lymphoma. </p><p>In a phase I trial we determined the maximum tolerated dose (MTD) of CHS 828. Haematological toxicity was generally mild and dominated by transient thrombocytopenia and lymphocytopenia. Non-haematological toxicity was mostly of gastrointestinal origin. The recommended phase two dose (RPTD) of CHS 828 was estimated to be 20 mg once daily for five days in cycles of 28 days duration.</p><p>In a phase II trial we investigated the effect of CHS 828 on patients diagnosed with B-CLL. In total 12 patients were enrolled. CHS 828 was found to be well tolerated and the most common haematological toxicity was thrombocytopenia. Non-haematological toxicities were generally mild. Transient decreases in lymphocyte counts could be discerned coinciding with drug dosing, but no sustained clinical responses could be achieved.</p><p>In conclusion, CHS 828 demonstrated marked effects in the preclinical investigations suggesting haematological malignancies as the main target. The clinical phase I study established a safe dose and the subsequent phase II trial in B-CLL patients showed biological effect but with no clinical disease response. </p>